CA2336419A1 - Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer - Google Patents

Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer Download PDF

Info

Publication number
CA2336419A1
CA2336419A1 CA002336419A CA2336419A CA2336419A1 CA 2336419 A1 CA2336419 A1 CA 2336419A1 CA 002336419 A CA002336419 A CA 002336419A CA 2336419 A CA2336419 A CA 2336419A CA 2336419 A1 CA2336419 A1 CA 2336419A1
Authority
CA
Canada
Prior art keywords
composition
tau
matter
carbons
halide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002336419A
Other languages
English (en)
French (fr)
Inventor
Hanno Roder
Timothy B. Lowinger
David R. Brittelli
Michael C. Vanzandt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2336419A1 publication Critical patent/CA2336419A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002336419A 1998-07-02 1999-06-23 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer Abandoned CA2336419A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/109,131 US6013646A (en) 1998-07-02 1998-07-02 Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US09/109,131 1998-07-02
PCT/EP1999/004369 WO2000001699A1 (en) 1998-07-02 1999-06-23 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Publications (1)

Publication Number Publication Date
CA2336419A1 true CA2336419A1 (en) 2000-01-13

Family

ID=22325955

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002336419A Abandoned CA2336419A1 (en) 1998-07-02 1999-06-23 Novel indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Country Status (6)

Country Link
US (2) US6013646A (US07794700-20100914-C00152.png)
EP (1) EP1091962A1 (US07794700-20100914-C00152.png)
JP (1) JP2002519425A (US07794700-20100914-C00152.png)
AU (1) AU754399B2 (US07794700-20100914-C00152.png)
CA (1) CA2336419A1 (US07794700-20100914-C00152.png)
WO (1) WO2000001699A1 (US07794700-20100914-C00152.png)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6660750B2 (en) 2000-02-15 2003-12-09 University Of Iowa Research Foundation Flavopiridol methods and compositions for HIV therapy
WO2001064199A2 (en) * 2000-02-29 2001-09-07 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with taxane compounds
WO2001085151A2 (en) * 2000-05-08 2001-11-15 Psoriasis Research Institute Chimeric animal model and treatment of psoriasis
US7129250B2 (en) * 2000-05-19 2006-10-31 Aegera Therapeutics Inc. Neuroprotective and anti-proliferative compounds
CA2308994A1 (en) * 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
JP2005511719A (ja) * 2001-12-13 2005-04-28 ファーマサイクリクス，インコーポレイテッド 神経性進行に影響を与えるためのプロセス
DE10161940A1 (de) * 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
CA2477604A1 (en) * 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
DE10255343B4 (de) * 2002-11-27 2006-09-07 Nad Ag N,N-Verbrückte, Stickstoff-Substituierte Carbacyclische Indolocarbazole als Proteinkinase-Inhibitoren
EP1737472B1 (en) 2004-03-29 2014-08-13 University Of South Florida Effective treatment of tumors and cancer with triciribine
US20100028339A1 (en) * 2004-03-29 2010-02-04 Cheng Jin Q Compositions including triciribine and trastuzumab and methods of use thereof
US20110008327A1 (en) * 2004-03-29 2011-01-13 Cheng Jin Q Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
US20100009928A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and taxanes and methods of use thereof
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20100173864A1 (en) 2004-03-29 2010-07-08 Cheng Jin Q Compositions including triciribine and one or more platinum compounds and methods of use thereof
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
EP1843734A4 (en) * 2005-02-03 2008-09-10 Signum Biosciences Inc COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
WO2006118630A2 (en) * 2005-05-02 2006-11-09 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of alzheimer's disease
US20070249590A1 (en) * 2005-10-28 2007-10-25 Wilson Lawrence J Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders
CN1870631B (zh) * 2005-11-11 2010-04-14 华为技术有限公司 媒体网关的门控方法
CA2672650C (en) * 2006-12-14 2015-09-08 Tautatis, Inc. Compositions and methods for the treatment of cancer
US20100273769A1 (en) * 2009-01-26 2010-10-28 Hanno Roder Composition and method for the treatment of parkinson's disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968690A (en) * 1986-05-27 1990-11-06 United States Government As Represented By The Secretary Of The Dept. Of Health And Human Services 3-deazaneplanocin, intermediates for it, and antiviral composition and method of treatment using it
EP0303697B1 (en) * 1987-03-09 1997-10-01 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance k-252
JPH07113027B2 (ja) * 1987-12-24 1995-12-06 協和醗酵工業株式会社 Ｋ−２５２誘導体
US5618809A (en) * 1989-12-14 1997-04-08 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes copiosa subsp. nov SCC 1951 ATCC 53856
US5189046A (en) * 1990-08-14 1993-02-23 Nova Pharmaceutical Corporation Protein kinase C modulators
JPH04187686A (ja) * 1990-11-20 1992-07-06 Meiji Seika Kaisha Ltd インドロカルバゾール誘導体
EP1026237B1 (en) * 1991-08-09 2004-03-24 Massachusetts Institute Of Technology Use of an inhibitor of Tau/neurofilament protein kinase PK40
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
EP0575955B1 (en) * 1992-06-22 1999-09-15 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
US5621101A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
CA2140653A1 (en) * 1992-08-12 1994-03-03 Irene Abraham Protein kinase inhibitors and related compounds combined with taxol
EP0643966A4 (en) * 1993-03-03 1995-08-09 Kyowa Hakko Kogyo Kk SENSITIVITY BOOSTER FOR ANTINEOPLASTIC AGENT.
US5516771A (en) * 1993-05-28 1996-05-14 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
EP1449529B1 (en) * 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US5654307A (en) * 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
WO1995022331A1 (en) * 1994-02-18 1995-08-24 Cephalon, Inc. Aqueous indolocarbazole solutions
US5491242A (en) * 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5594009A (en) * 1994-10-14 1997-01-14 Cephalon, Inc. Fused pyrrolocarbazoles
US5648378A (en) * 1995-06-07 1997-07-15 Research Corporation Technologies, Inc. 2-iminochromene derivatives as inhibitors of protein tyrosine kinase
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer

Also Published As

Publication number Publication date
AU4776699A (en) 2000-01-24
WO2000001699A1 (en) 2000-01-13
EP1091962A1 (en) 2001-04-18
US6013646A (en) 2000-01-11
AU754399B2 (en) 2002-11-14
JP2002519425A (ja) 2002-07-02
US6541468B1 (en) 2003-04-01

Similar Documents

Publication Publication Date Title
US6013646A (en) Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
EP2306836B1 (en) Bmi-1 protein expression modulators
CA2906156C (en) Transient protection of normal cells during chemotherapy
US20040102467A1 (en) Neuroprotective and anti-proliferative compounds
EP2155675B1 (en) Kinase inhibitors, compositions thereof, and methods of use therewith
US20130274258A1 (en) Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
TW201605860A (zh) 吡唑并嘧啶化合物
JP2019520426A (ja) がん治療の組み合わせ
CN110891942B (zh) 噁二唑类衍生物、其制备方法及其在医药上的应用
WO2007136635A1 (en) Enhancement of radiation therapy and/or chemotherapy with acid ceramidase modulators
US20060199835A1 (en) Neuroprotective and anti-proliferative compounds
US11787794B2 (en) Aminothiazole compounds and methods using same
EA029372B1 (ru) Пиразолопиримидиновые соединения
KR20050072764A (ko) 벤조피라논 화합물, 그것의 조성물 및 암 치료 또는 예방방법
WO2019010180A1 (en) PEPTIDE AND SMALL MOLECULE AGONISTS OF EPHA AND USES THEREOF
WO2014089571A1 (en) Anticancer compounds
CA2409355A1 (en) Neuroprotective and anti-proliferative compounds

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued